Bausch Health Companies Inc. BHC

Updated: 11 Jun 2026

NYSE | Biotech | Pharmaceuticals and eye health

No signal published yet

We already track Bausch Health Companies and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow Bausch Health Companies free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NYSE
Type
Biotech
Sector
Pharmaceuticals and eye health
We're already tracking Bausch Health Companies Inc. — here are the latest events we've registered

Recent News

  • On June 9, 2026, Bausch Health announced a letter of intent for public drug plan coverage of its schizophrenia treatment OKEDI in Canada. The company also reported its first-quarter 2026 results on April 29, showing a 12% revenue increase to $2.52 billion compared to the prior year.

What Firelda Watch includes for Bausch Health Companies Inc.

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Bausch Health Companies Inc. will be delivered in the same format.

Want to follow Bausch Health Companies Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow Bausch Health Companies free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Bausch Health Companies Inc. BHC
Bausch Health Companies — follow and we'll monitor it
Follow Bausch Health Companies free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.